Vir Biotechnology (NASDAQ:VIR) Stock: Insider Verneuil Vanina De Sells 1,343 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Vanina de Verneuil sold 1,343 shares of Vir Biotechnology stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $11.33, for a total value of $15,216.19. Following the sale, the executive vice president owned 112,600 shares of the company’s stock, valued at approximately $1,275,758. This trade represents a 1.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Verneuil Vanina De also recently made the following trade(s):

• On Tuesday, November 3rd, Vanina de Verneuil sold 2,407 shares of Vir Biotechnology stock. The shares were sold at an average price of $11.10, for a total transaction of $26,717.70.

Vir Biotechnology Trading Up 3.3%

Shares of NASDAQ VIR traded up $0.37 during mid-day trading on Wednesday, reaching $11.59. The company had a trading volume of 1,277,018 shares, compared to its average volume of 2,354,576. The business’s 50-day moving average is $10.99 and its 200-day moving average is $9.53. The stock has a market cap of $1.96 billion, a price-to-earnings ratio of -6.23 and a beta of 1.70. Vir Biotechnology, Inc. has a 52 week low of $4.82 and a 52 week high of $12.19.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.47 earnings per share for the quarter, beating analysts’ consensus estimates of $0.33 by $0.14. The company had revenue of $238.95 million for the quarter, compared to the consensus estimate of $135.88 million. The company’s quarterly revenue was up 19582.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.80) EPS. As a group, equities research analysts forecast that Vir Biotechnology, Inc. will post -1.84 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on VIR. Wall Street Zen raised Vir Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Friday, October 2nd. HC Wainwright upped their target price on Vir Biotechnology from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Wednesday, October 7th. Zacks Research downgraded Vir Biotechnology from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 6th. Finally, Raymond James Financial restated a “strong-buy” rating on shares of Vir Biotechnology in a research note on Monday, September 28th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $21.86.

Hedge Funds Weigh In On Vir Biotechnology

Hedge funds and other institutional investors have recently modified their holdings of the business. Fiduciary Financial Advisors purchased a new position in Vir Biotechnology during the second quarter valued at approximately $29,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Vir Biotechnology during the third quarter worth $97,000. Caxton Associates LLP purchased a new stake in Vir Biotechnology during the first quarter worth $112,000. Amundi lifted its holdings in Vir Biotechnology by 52.8% during the first quarter. Amundi now owns 15,315 shares of the company’s stock worth $137,000 after buying an additional 5,294 shares during the period. Finally, Royal Bank of Canada boosted its position in Vir Biotechnology by 223.1% during the 1st quarter. Royal Bank of Canada now owns 15,355 shares of the company’s stock valued at $138,000 after acquiring an additional 10,603 shares in the last quarter. 65.32% of the stock is currently owned by institutional investors.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical-stage immunology company focused on developing medicines to prevent and treat serious infectious diseases and other immune-related conditions. The company uses antibody engineering, immunologic approaches and other technologies to identify and advance therapies designed to harness or modify the immune system.

Vir’s research and development programs have included treatments and vaccines for hepatitis B, human immunodeficiency virus (HIV), influenza and other infectious diseases.